Carol H Lin - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Carol H Lin

Showing results (1-10 of 3) with videos related to

Pageof 1

Sort By:

Advances in Experimental Medicine and Biology|June 14, 2014

Wnt signaling in osteosarcomaCarol H Lin, Tao Ji, Cheng-Fong Chen, et al.

Sarcoma|March 12, 2013

Dkk-3, a secreted wnt antagonist, suppresses tumorigenic potential and pulmonary metastasis in osteosarcomaCarol H Lin, Yi Guo, Samia Ghaffar, et al.

Blood Advances|January 22, 2025

Pediatric relapsed/refractory ALK-positive anaplastic large cell lymphoma treatment and outcomes in the targeted-drug eraLianna J Marks, Victor Ritter, Jennifer E Agrusa, et al.

Pageof 1

Search research articles

Showing results (1-10 of 3) with videos related to

Sort By:

Pageof 1

Advances in Experimental Medicine and Biology|June 14, 2014

Wnt signaling in osteosarcomaCarol H Lin, Tao Ji, Cheng-Fong Chen, et al.

Sarcoma|March 12, 2013

Dkk-3, a secreted wnt antagonist, suppresses tumorigenic potential and pulmonary metastasis in osteosarcomaCarol H Lin, Yi Guo, Samia Ghaffar, et al.

Blood Advances|January 22, 2025

Pediatric relapsed/refractory ALK-positive anaplastic large cell lymphoma treatment and outcomes in the targeted-drug eraLianna J Marks, Victor Ritter, Jennifer E Agrusa, et al.

Pageof 1